Cellectis Shareholders Meeting Adopts 29 Resolutions, Rejects One
Cellectis, a clinical-stage biotechnology company, held its shareholders general meeting in Paris. The meeting saw 29 resolutions adopted and one rejected, aligning with board recommendations.
Paris – Cellectis, a clinical-stage biotechnology company, convened its shareholders general meeting on June 25, 2026, in Paris. Approximately 55.84% of the voting rights were exercised during the meeting.
The shareholders adopted resolutions 1 through 29. Resolution 30 was rejected by the attendees. The outcome followed the recommendations set forth by the company's board of directors.
Cellectis utilizes its gene-editing platform to develop cell and gene therapies. The company's securities are listed on Euronext Growth (ALCLS) and NASDAQ (CLLS).
Detailed voting results and the adopted resolutions have been published on Cellectis' investor relations website.